BCRX BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. (BCRX) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is $0.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.2% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About BioCryst Pharmaceuticals, Inc.
Biocryst Pharmaceuticals Inc is a biotechnology company. The Company designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
Sector
Healthcare
Industry
Drug Manufacturers/Other